1Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/AC- CP/ATS/SIS International Sepsis Definitions Conference [ J ]. Crit Care Med,2003,31 (4) :1250 - 1256.
2Martin GS, Mannino DM, Eaton S, et al. The epidemiology of sepsis in the United States from 1979 through 2000 [J]. N Engl J Med, 2003,348 (16) : 1546 - 1554.
3Angus DC, Linde - Zwirble WT, Lidicker J, et al. Epidemiology of se- vere sepsis in the United States: analysis of incidence, outcome, and associated costs of care[J]. Crit Care Med,2001,29(7) :1303 -1310.
4Annane D, Bellissant E, Cavaillon JM. Septic shock [ J ]. Lancet, 2005,365 (9453) :63 - 78.
5Annane D, Aegerter P, Jars - Guincestre MC, et al. Current epide- miology of septic shock: the CUB - Rea Network [ J]. Am J Respir Crit Care Med,2003,168(2) :165 -172.
6Fumeaux T, Pugin J. Role of interleukin - 10 in the intracellular se- questration of human leukocyte antigen - DR in monocytes during septic shock [ J ]. Am J Respir Crit Care Med,2002,166 ( 11 ) : 1475 - 1482.
7Le Tulzo Y, Pangault C, Amiot L, et al. Monocyte human leukocyte antigen - DR transcriptional downregulation by cortisol during septic shock[J]. Am J RespirCrit Care Med,2004,169(10) :1144 -1151.
8Annane D, Sebille V, Troche G, et al. A 3 - level prognostic classifi- cation in septic shock based on cortisol levels and cortisol response to eorticotropin [ J ]. JAMA ,2000,283 (8) : 1038 - 1045.
9Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock [ J ]. JAMA,2002,288 (7) :862 - 871.
10Laviolle B, Annane D, Fougerou C, et al. Gluco - and mineralocor- ticoid biological effects of a 7 - day treatment with low doses of hydro- cortisone and fludrocortisone in septic shock[ J]. Intensive Care Med, 2012,38(8) :1306 - 1314.
5Faber J, Berkhout M, Vos AP, et al. Supplementation with a fish oil-enriched, high-protein medical food leads to rapid incorporation of EPA into white blood cells and modulates immune responses with- in one week in healthy men and women[J]. J Nutr, 2011,14( 1 ) : 964 - 970.
6CALVANO S E,XIAO W, RICHARDS D R, et al. A network- based analysis of systemic inflammation in humans [ J ]. Na- ture ,2005,437 (7061) : 1032-1037.
7VENET F, LUKASZEWICZ A C, PAYEN D, et al. Monitoring the immune response in sepsis:a rational approach to adminis- tration of immunoadjuvant therapies [ J ]. Curr Opin Immanol, 2013,25( 1 ) :477-483.
8BONE R C. Sir Isaac Newton,sepsis, SIRS, and CARS [ J ]. Crit Care Med, 1996,24 (7) : 1125-1128.
9OSUCHOWSKI M F,WELCH K,YANG H,et al. Chronic sep- sis mortality characterized by an individualized inflammatory response [ J ]. Immuno1,2007,179 ( 1 ) 623- 630.
10GOGOS C, KOTSAKI A, PELEKANOU A, et al. Early altera- tions of the innate and adaptive immune statuses in sepsis ac- cording to the type of the underlying infection [ J ]. Crit Care, 2010,14(3) :96-100.
